ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$4.40
-0.37 (-7.76%)
▼
5d:
-8.71%
30d:
+13.99%
90d:
+49.66%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
ABCL is down 8.7% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 5,937 OI. Call ratio: 88% View Scanner →
Strength: 8.2/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
12 traders called ABCL this week
89% bullish • 3 bearish
89% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $4.40, which is considered fair relative to its 30-day fair value range of $3.62 to $4.72.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $4.03, while resistance sits at $5.63. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: ABCL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.71 (+120.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $4.03, while resistance sits at $5.63. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: ABCL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.71 (+120.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.62 -
$4.72
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 120.8% below Wall St target ($9.71)
- CAUTION: Recommendation downgraded due to -8.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.62 -
$4.72
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.03
Resistance Level
$5.63
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.17
Wall Street Target
$9.71
(+120.8%)
Revenue Growth (YoY)
96.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-181.7%
Share & Embed Analysis
Last updated: May 14, 2026 6:35 PM ET
Data refreshes hourly during market hours. Next update: 7:35 PM
Data refreshes hourly during market hours. Next update: 7:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
